NASDAQ:OKYO OKYO Pharma (OKYO) Stock Price, News & Analysis $1.46 -0.01 (-0.68%) Closing price 03:54 PM EasternExtended Trading$1.48 +0.02 (+1.30%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About OKYO Pharma Stock (NASDAQ:OKYO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get OKYO Pharma alerts:Sign Up Key Stats Today's Range$1.46▼$1.4950-Day Range$1.29▼$1.6852-Week Range$1.26▼$3.20Volume30,442 shsAverage Volume144,503 shsMarket Capitalization$76.62 millionP/E RatioN/ADividend YieldN/APrice Target$5.67Consensus RatingModerate Buy Company Overview OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biotechnology company developing therapies for diseases driven by inflammation and immune-system dysfunction. The company uses a drug-discovery platform focused on G protein-coupled receptors (GPCRs), a broad class of biological targets involved in pain, inflammation and other disease processes. OKYO’s lead candidate, OK-101, is being developed as a locally acting treatment for ocular diseases, including dry eye disease and neuropathic corneal pain. The company has also investigated additional potential applications for its GPCR-targeted drug candidates in inflammatory and immunological conditions. OKYO Pharma was established in the United Kingdom and is listed on the Nasdaq Capital Market. Its research and development activities are focused on advancing internally discovered therapies through clinical development. The company is led by Chief Executive Officer Gary S. Jacob, a biotechnology executive and scientist with experience in GPCR drug discovery.AI Generated. May Contain Errors. Read More OKYO Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreOKYO MarketRank™: OKYO Pharma scored higher than 44% of companies evaluated by MarketBeat, and ranked 571st out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingOKYO Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOKYO Pharma has a consensus price target of $5.67, representing about 288.1% upside from its current price of $1.46.Amount of Analyst CoverageOKYO Pharma has only been the subject of 2 research reports in the past 90 days.Read more about OKYO Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for OKYO Pharma are expected to decrease in the coming year, from ($0.22) to ($0.52) per share.Price to Book Value per Share RatioOKYO Pharma has a P/B Ratio of 4.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about OKYO Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.13% of the float of OKYO Pharma has been sold short.Short Interest Ratio / Days to CoverOKYO Pharma has a short interest ratio ("days to cover") of 0.46, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OKYO Pharma has recently decreased by 22.35%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOKYO Pharma does not currently pay a dividend.Dividend GrowthOKYO Pharma does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 5 news articles for OKYO Pharma this week, compared to 2 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OKYO Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.97% of the stock of OKYO Pharma is held by institutions.Read more about OKYO Pharma's insider trading history. Receive OKYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OKYO Stock News HeadlinesOKYO Pharma Begins Phase 3 Trial Of Urcosimod For Neuropathic Corneal Pain4 hours ago | rttnews.comOKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain4 hours ago | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 6 at 1:00 AM | Porter & Company (Ad)OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drugOctober 6 at 8:42 AM | proactiveinvestors.comOKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal PainOctober 6 at 7:00 AM | globenewswire.comOKYO Pharma (NASDAQ:OKYO) Stock Price Up 9.7% - Still a Buy?October 3 at 1:41 AM | americanbankingnews.comOKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific ConferencesSeptember 29, 2026 | globenewswire.comOKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026September 9, 2026 | globenewswire.comSee More Headlines OKYO Stock Analysis - Frequently Asked Questions How have OKYO shares performed this year? OKYO Pharma's stock was trading at $2.07 at the start of the year. Since then, OKYO stock has decreased by 29.5% and is now trading at $1.46. When did OKYO Pharma IPO? OKYO Pharma (OKYO) raised $2 million in an IPO on Tuesday, May 17th 2022. The company issued 625,000 shares at a price of $4.00 per share. How do I buy shares of OKYO Pharma? Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OKYO Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Meta Platforms (META), Intel (INTC), NVIDIA (NVDA), C3.ai (AI), Bristol Myers Squibb (BMY), Energy Transfer (ET) and Ford Motor (F). Company Calendar Today10/06/2026Next Earnings (Estimated)12/02/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 OKYO's financial health is in the Yellow zone, according to TradeSmith. OKYO has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:OKYO CIK1849296 Webwww.okyopharma.com Phone44-20-7495-2379FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for OKYO Pharma$5.67 High Price Target$7.00 Low Price Target$5.00 Potential Upside/Downside+288.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio2.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book4.87Miscellaneous Outstanding Shares52,480,000Free Float31,247,000Market Cap$76.62 million OptionableNot Optionable Beta0.05 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:OKYO) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKYO Stock Alerts